Sector News

Alexion concedes to activists, joins forces on director search

January 3, 2018
Life sciences

Alexion and activist investor Elliott Management are putting their differences aside.

The two parties have agreed to “work collaboratively” to find a new member for Alexion’s board, they said late Tuesday. Alexion had announced back in November that it was looking to fill an open seat.

The agreement follows a December report that Elliott had built up a stake in the rare-disease drugmaker and was looking for a bigger effort from the company’s leaders to boost share prices. The fund also wanted to see more biotech experience on Alexion’s slate of directors, according to The New York Times—particularly now that Ludwig Hantson, the former helmsman of Baxalta, had filled key leadership positions with his pharma peers.

“This agreement is in line with our ongoing efforts to maintain active and constructive dialogue with all of our shareholders and to identify a new board member with a proven track record of building value,” Chairman David Brennan said in a statement.

At least one analyst likely wasn’t surprised to see activists jump into the mix at Alexion, which spent 2017 working to find its footing after key leaders departed amid a late-2016 sales-fraud investigation. Leerink Partners’ Geoffrey Porges has called the biotech “one of the rare, once or twice per decade, activist investment situations in the biopharmaceutical industry.”

Elliott, though, seems to like what it’s seen over the last couple of months from Hantson, whose moves have included hundreds of layoffs and a headquarters relocation. “We are encouraged by actions taken under Ludwig’s leadership to improve financial performance and reset Alexion’s strategy,” a spokesperson said in a statement.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach